EGFR and non-small cell lung carcinoma: In contrast, males typically metabolize and eliminate gemcitabine more efficiently, which may enhance its therapeutic effects while reducing side effects.[25] Additionally, females with NSCLC are more likely to have EGFR mutations, which respond better to targeted EGFR inhibitors rather than chemotherapy.